Drugs / TNX-2120
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05216510 | Jan → Sep 2022 | type IV hypersensitivity disease | Tonix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNX-2120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05216510 ↗ |
| Route | Other | “TNX-2120 represents the spike protein and is administered intradermally.” NCT05216510 ↗ |